Christopher K. Mutz
2021
In 2021, Christopher K. Mutz earned a total compensation of $1.6M as Head of Rare Disease at ANI Pharmaceuticals.
Compensation breakdown
| Bonus | $247,482 |
|---|---|
| Option Awards | $502,697 |
| Salary | $338,462 |
| Stock Awards | $508,060 |
| Other | $9,231 |
| Total | $1,605,932 |
Mutz received $508.1K in stock awards, accounting for 32% of the total pay in 2021.
Mutz also received $247.5K in bonus, $502.7K in option awards, $338.5K in salary and $9.2K in other compensation.
Rankings
In 2021, Christopher K. Mutz's compensation ranked 6,959th out of 12,415 executives tracked by ExecPay. In other words, Mutz earned more than 43.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,959 out of 12,415 | 44th |
Division Manufacturing | 3,045 out of 5,505 | 45th |
Major group Chemicals And Allied Products | 1,349 out of 2,375 | 43rd |
Industry group Drugs | 1,204 out of 2,096 | 43rd |
Industry Pharmaceutical Preparations | 877 out of 1,546 | 43rd |
Pay ratio
| Christopher K. Mutz's Pay | $1,605,932 |
|---|---|
| Median Employee's Pay | $50,403 |
| Pay Ratio | 32to 1 |
In 2021, the annual total compensation of Christopher K. Mutz was $1,605,932.
The annual total compensation of the median employee at ANI Pharmaceuticals was $50,403.
The ratio of Christopher K. Mutz's pay to the pay of median employee was therefore 32 to one.
Source: SEC filing on March 25, 2022.
Mutz's colleagues
We found four more compensation records of executives who worked with Christopher K. Mutz at ANI Pharmaceuticals in 2021.